Transthyretin Cardiac Amyloidosis Fellowship

Transthyretin Cardiac Amyloidosis Fellowship is sponsored by Pfizer Inc.. This competitive fellowship program is designed to advance the training of healthcare professionals—specifically cardiologists or heart failure advanced practice providers—in recognizing, diagnosing, and managing transthyretin cardiac amyloidosis (ATTR-CM).

# Pfizer Announces a Fellowship Grant RFP # Transthyretin Cardiac Amyloidosis Fellowship-United States # Competitive Grant Program – using expert review panel Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.

Pfizer’s GMG competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest, sets timelines for review and approval, and uses an expert review panel (ERP). Institutions are invited to submit an application as outlined in the specific RFP.

This RFP reflects Pfizer’s commitment to advancing research, innovation, a n d training for medical, nursing, and allied health professionals. 31 ATTR-CM Fellowship- United States II. Eligibility Geographic Scope: United States Applicant Eligibility Criteria • Accredited, US-based academic institution.

• Do not include the name of the potential fellow(s) in application materials. This grant will be awarded to an institution, not an individual. • Institutions with fellowship programs that include independent research and a strong mentoring program.

Clinical training may be included in the program but is not required. • No aspect of the fellowship program can benefit Pfizer’s business or a Pfizer asset. • Examples of independent research include: observational studies and outcomes research studies where the primary focus is the scientific understanding of disease; use of screening tools and their impact on improvement of patient health.

o Examples of research that would not be eligible include research involving the study and/or evaluation of any pharmaceutical product and basic science and/or fundamental research (in animal model, in-vitro, etc.).

• Examples of clinical training include: educational time with an interdisciplinary team in review of case examples and relevant didactic training as well as use of tools for improvement in patient health for specific therapeutic areas or conditions. • Fellow time spent in the clinical setting that is supported through grant funds must not be billed as patient care. III.

Requirements Date RFP Issued • March 1, 2022 Specific Area of Interest for this RFP • It is our intent to support institutions with fellowship programs for Cardiologists that have a strong focus on clinical practice, research, and education to further the understanding of transthyretin cardiac amyloidosis.

• Grants will be available for both established and emerging Transthyretin Cardiac Amyloidosis Fellowship programs Requirements for Prospective Fellows: • Institution must ensure that any fellow that will receive grant funds must be a U.S. Worker (U.S. citizen, permanent resident, refugee, or asylee), or hold an appropriate non-immigrant visa status authorizing employment in the U.S. • U.S. Physician Payments Sunshine Act (“Sunshine Act”) and other transparency law requirements must be satisfied with respect to meals, 32 ATTR-CM Fellowship- United States payments and other transfers of value.

As a condition of the grant, the selected fellow will be named in transparency reporting as a recipient of grant funding. Budget: • Grant funding is available to support one fellow for up to a year at $80,000. Grant will be available for both established and emerging programs • There is a total budget of $240,000 for this program.

• The budget may only include salary and support of the fellow benefits. Grant funds cannot be used for overhead or indirect costs. • Funding will be awarded to the institution, not an individual.

• Fellow time spent in the clinical setting that is supported through grant funds must not be billed as patient care. • No aspect of the fellowship program budget can reflect a benefit to Pfizer’s business or a Pfizer asset. Key Dates: • RFP release date: March 1, 2022 • Full Proposal Deadline Extended to July 18, 2022 Please note the deadline is midnight Eastern Time (New York, GMT -5).

• Review of Full Proposals by External Review Panel: August 2022 • Anticipated Full Proposal Notification Date: August 2022 • Grants distributed following execution of fully signed contract • Anticipated Project Start and End Dates: July 2023 to June 2024 • Click the “Start A New Fellowship Application” button.

• Select the following Competitive Grant Program Name: 2022 RD US Cardiac Amyloidosis Fellowship US • Requirements for submission: • Complete all required sections of the online application • Upload Proposal (see Appendix). You must upload a Proposal. Click here to access the template for the Proposal.

• If you encounter any technical difficulties with the website, please click the “Technical Questions” link at the bottom of the page. 33 ATTR-CM Fellowship- United States Questions: • If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Amanda Stein (amanda. j.

stein@pfizer. com), with the subject line “2022 RD US – Cardiac Amyloidosis Fellowship US” Review and Approval Process • A specific grant program RFP uses an expert review panel (ERP) to make final grant decisions.

• The panels are comprised of professionals from the medical community with advanced degrees and expertise in particular clinical areas, or specific needs of a geographic region/learner group, or expertise in research, continuing professional development or quality improvement Mechanism by which Applicants will be Notified: • All applicants will be notified via email by the dates noted above.

• Applicants may be asked for additional clarification during the review period. 34 ATTR-CM Fellowship- United States Appendix A Proposal Requirements Please click here to download the Proposal Template which includes the fields listed below. This document should be formatted with single-spaced using 12-point font and 1-inch margins and should not exceed 10-15 pages.

Cover Page (not to exceed 1 page) • Title: Please include the fellowship title, and main institutions • Abstract: Please include an abstract summary of your proposal including the goal of the fellowship, methods the institution uses to support the fellow’s training and research, and assessment. Overall Goals and Objectives of the Fellowship • Describe the overall goal of the fellowship.

• Describe the focus of research and/or clinical training as applicable that is being supported in general terms based on the categorizations listed in this application. Methods • Please describe the mentoring process. • Include a description of the methods used to support the fellow and their research and/or clinical training (e.g. details on research training opportunities, how will they will develop their skills?)

Resources • Please describe the institution’s academic, clinical training, and research capacity. • Describe the facilities/resources that are made available to the fellow. • Provide a summary of relevant past work that is applicable.

Challenges • Please provide a summary of potential challenges and of plans for addressing those challenges Institutional Support • Division Head/ Department Chair Letter of Support.

• Primary mentor; Secondary mentor (if applicable) Letter of Support Budget • Budget: Address any additional sources of financial support for this proposal, including current and pending sources of funding • Any request for funds beyond salary support will not be provided as part of the award 35 ATTR-CM Fellowship- United States Anticipated Project Timeline • Provide an anticipated timeline for your project including project start/end dates Additional Information • What year was this specific Fellowship Program established?

• If there is any additional information you feel Pfizer should be aware of concerning the importance of this project, please summarize here